Ceritinib as a promising therapy for ALK related diseases

The journal article “Ceritinib in ALK-rearranged non-small-cell lung cancer”, published last 27th of March on the New England Journal of Medicine (N Engl J Med), reports for the first time the clinical data from the phase 1 study on the anaplastic lymphoma kinase (ALK) inhibitor ceritinib, also known as LDK-378 (Novartis)